{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T09:27:11Z","timestamp":1787390831108,"version":"build-2736575974"},"reference-count":162,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T00:00:00Z","timestamp":1781740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T00:00:00Z","timestamp":1781740800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Pharming Healthcare, Inc."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s12325-026-03656-7","type":"journal-article","created":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T08:21:06Z","timestamp":1781770866000},"page":"3828-3856","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Diverse Trial Designs, Populations, and Outcomes: A Systematic Literature Review of Trials for the Treatment of Hereditary Angioedema Attacks"],"prefix":"10.1007","volume":"43","author":[{"given":"Raffi","family":"Tachdjian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-5183-9153","authenticated-orcid":false,"given":"Nihal","family":"Narsipur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paranjoy","family":"Saharia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sakshi","family":"Jindal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nami","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph R.","family":"Harper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anurag","family":"Relan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Harrington","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,18]]},"reference":[{"issue":"1","key":"3656_CR1","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.jaip.2020.08.046","volume":"9","author":"PJ Busse","year":"2021","unstructured":"Busse PJ, Christiansen SC, Riedl MA, et al. US HAEA medical advisory board 2020 guidelines for the management of hereditary angioedema. J Allergy Clin Immunol Pract. 2021;9(1):132-50.e3.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"1","key":"3656_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.waojou.2021.100621","volume":"15","author":"DH Jones","year":"2022","unstructured":"Jones DH, Bansal P, Bernstein JA, et al. Clinical profile and treatment outcomes in patients with hereditary angioedema with normal C1 esterase inhibitor. World Allergy Organ J. 2022;15(1):100621.","journal-title":"World Allergy Organ J"},{"issue":"6","key":"3656_CR3","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1177\/0091217419837068","volume":"54","author":"\u00d6 Kuman Tun\u00e7el","year":"2019","unstructured":"Kuman Tun\u00e7el \u00d6, G\u00f6kmen NM, Demir E, G\u00fclbahar O, P\u0131r\u0131ldar \u015e. The impact of hereditary angioedema on quality of life and family planning decisions. Int J Psychiatry Med. 2019;54(6):377\u201394.","journal-title":"Int J Psychiatry Med"},{"issue":"7","key":"3656_CR4","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1111\/all.15214","volume":"77","author":"M Maurer","year":"2022","unstructured":"Maurer M, Magerl M, Betschel S, et al. The international WAO\/EAACI guideline for the management of hereditary angioedema\u2013the 2021 revision and update. Allergy. 2022;77(7):1961\u201390. https:\/\/doi.org\/10.1111\/all.15214.","journal-title":"Allergy"},{"issue":"5","key":"3656_CR5","doi-asserted-by":"publisher","first-page":"407","DOI":"10.2500\/aap.2010.31.3394","volume":"31","author":"WR Lumry","year":"2010","unstructured":"Lumry WR, Castaldo AJ, Vernon MK, et al. The humanistic burden of hereditary angioedema: impact on health-related quality of life, productivity, and depression. Allergy Asthma Proc. 2010;31(5):407\u201314. https:\/\/doi.org\/10.2500\/aap.2010.31.3394.","journal-title":"Allergy Asthma Proc"},{"issue":"1","key":"3656_CR6","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-024-03265-z","volume":"19","author":"X Guan","year":"2024","unstructured":"Guan X, Sheng Y, Liu S, et al. Epidemiology, economic, and humanistic burden of hereditary angioedema: a systematic review. Orphanet J Rare Dis. 2024;19(1):256.","journal-title":"Orphanet J Rare Dis"},{"issue":"8","key":"3656_CR7","doi-asserted-by":"publisher","first-page":"2432","DOI":"10.1016\/j.jaip.2023.03.006","volume":"11","author":"NS Arora","year":"2023","unstructured":"Arora NS, Nelson B, Carpenter L, et al. Consequences of insurance coverage delays and denials for patients with hereditary angioedema. J Allergy Clin Immunol Pract. 2023;11(8):2432-38.e1. https:\/\/doi.org\/10.1016\/j.jaip.2023.03.006.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"3656_CR8","doi-asserted-by":"publisher","DOI":"10.1111\/all.70207","author":"H Farkas","year":"2026","unstructured":"Farkas H, Martinez-Saguer I, Bork K, et al. International guideline on the diagnosis and management of pediatric patients with hereditary angioedema. Allergy. 2026. https:\/\/doi.org\/10.1111\/all.70207.","journal-title":"Allergy"},{"key":"3656_CR9","unstructured":"Kalbitor (ecallantide) [prescribing information]. Cambridge, MA: Takeda Pharmaceuticals USA, Inc; 2025."},{"key":"3656_CR10","unstructured":"Firazyr (icatibant) [prescribing information]. Cambridge, MA: Takeda Pharmaceuticals America, Inc.; 2025."},{"key":"3656_CR11","unstructured":"Berinert (C1 esterase inhibitor [human]) [prescribing information]. Marburg, Germany: CSL Behring GmbH; 2021."},{"key":"3656_CR12","unstructured":"Ruconest (C1 esterase inhibitor [recombinant]) [prescribing information]. Leiden, The Netherlands: Pharming Healthcare, Inc.; 2020."},{"key":"3656_CR13","unstructured":"EKTERLY (sebetralstat) [prescribing information]. Cambridge, MA: KalVista Pharmaceuticals, Inc.; 2025."},{"issue":"4","key":"3656_CR14","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1016\/j.jaci.2009.07.017","volume":"124","author":"TJ Craig","year":"2009","unstructured":"Craig TJ, Levy RJ, Wasserman RL, et al. Efficacy of human C1 esterase inhibitor concentrate compared with placebo in acute hereditary angioedema attacks. J Allergy Clin Immunol. 2009;124(4):801\u20138.","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"3656_CR15","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1016\/j.jaci.2007.04.028","volume":"120","author":"L Schneider","year":"2007","unstructured":"Schneider L, Lumry W, Vegh A, Williams AH, Schmalbach T. Critical role of kallikrein in hereditary angioedema pathogenesis: a clinical trial of ecallantide, a novel kallikrein inhibitor. J Allergy Clin Immunol. 2007;120(2):416\u201322.","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"3656_CR16","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1056\/NEJMoa0906393","volume":"363","author":"M Cicardi","year":"2010","unstructured":"Cicardi M, Banerji A, Bracho F, et al. Icatibant, a new bradykinin-receptor antagonist, in hereditary angioedema. N Engl J Med. 2010;363(6):532\u201341.","journal-title":"N Engl J Med"},{"issue":"6","key":"3656_CR17","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1056\/NEJMoa0905079","volume":"363","author":"M Cicardi","year":"2010","unstructured":"Cicardi M, Levy RJ, McNeil DL, et al. Ecallantide for the treatment of acute attacks in hereditary angioedema. N Engl J Med. 2010;363(6):523\u201331.","journal-title":"N Engl J Med"},{"issue":"6","key":"3656_CR18","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/j.anai.2010.04.012","volume":"104","author":"RJ Levy","year":"2010","unstructured":"Levy RJ, Lumry WR, McNeil DL, et al. EDEMA4: a phase\u00a03, double-blind study of subcutaneous ecallantide treatment for acute attacks of hereditary angioedema. Ann Allergy Asthma Immunol. 2010;104(6):523\u20139. https:\/\/doi.org\/10.1016\/j.anai.2010.04.012.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"2","key":"3656_CR19","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.anai.2013.12.004","volume":"112","author":"MA Riedl","year":"2014","unstructured":"Riedl MA, Bernstein JA, Li H, et al. Recombinant human C1-esterase inhibitor relieves symptoms of hereditary angioedema attacks: phase\u00a03, randomized, placebo-controlled trial. Ann Allergy Asthma Immunol. 2014;112(2):163-69. e1.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"6","key":"3656_CR20","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/j.anai.2011.08.015","volume":"107","author":"WR Lumry","year":"2011","unstructured":"Lumry WR, Li HH, Levy RJ, et al. Randomized placebo-controlled trial of the bradykinin B2 receptor antagonist icatibant for the treatment of acute attacks of hereditary angioedema: the FAST-3 trial. Ann Allergy Asthma Immunol. 2011;107(6):529-37. e2.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"10375","key":"3656_CR21","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1016\/s0140-6736(22)02406-0","volume":"401","author":"E Ayg\u00f6ren-P\u00fcrs\u00fcn","year":"2023","unstructured":"Ayg\u00f6ren-P\u00fcrs\u00fcn E, Zanichelli A, Cohn DM, et al. An investigational oral plasma kallikrein inhibitor for on-demand treatment of hereditary angioedema: a two-part, randomised, double-blind, placebo-controlled, crossover phase\u00a02 trial. Lancet. 2023;401(10375):458\u201369. https:\/\/doi.org\/10.1016\/s0140-6736(22)02406-0.","journal-title":"Lancet"},{"issue":"4","key":"3656_CR22","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1016\/j.jaci.2010.07.021","volume":"126","author":"B Zuraw","year":"2010","unstructured":"Zuraw B, Cicardi M, Levy RJ, et al. Recombinant human C1-inhibitor for the treatment of acute angioedema attacks in patients with hereditary angioedema. J Allergy Clin Immunol. 2010;126(4):821-27. e14.","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"3656_CR23","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1056\/NEJMoa2314192","volume":"391","author":"MA Riedl","year":"2024","unstructured":"Riedl MA, Farkas H, Ayg\u00f6ren-P\u00fcrs\u00fcn E, et al. Oral sebetralstat for on-demand treatment of hereditary angioedema attacks. N Engl J Med. 2024;391(1):32\u201343. https:\/\/doi.org\/10.1056\/NEJMoa2314192.","journal-title":"N Engl J Med"},{"issue":"7","key":"3656_CR24","doi-asserted-by":"publisher","first-page":"2222","DOI":"10.1111\/all.15244","volume":"77","author":"LM Fijen","year":"2022","unstructured":"Fijen LM, Petersen RS, Cohn DM. Outcome measures in randomized controlled studies of acute therapy for hereditary angioedema: a systematic review. Allergy. 2022;77(7):2222.","journal-title":"Allergy"},{"key":"3656_CR25","unstructured":"Institute for Clinical and Economic Review (ICER). 2020\u20132023 value assessment framework. 2022. https:\/\/icer.org\/wp-content\/uploads\/2020\/11\/ICER_2020_2023_VAF_02032022.pdf. Accessed 25 Jul 2025."},{"key":"3656_CR26","unstructured":"National Institute for Health and Care Excellence (NICE). Single technology appraisal and highly specialised technologies evaluation: user guide for company evidence submission template 2024. https:\/\/www.nice.org.uk\/process\/pmg24\/resources\/single-technology-appraisal-and-highly-specialised-technologies-evaluation-user-guide-for-company-evidence-submission-template-pdf-72286715419333. Accessed 25 Jul 2025."},{"key":"3656_CR27","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.","journal-title":"BMJ"},{"key":"3656_CR28","unstructured":"Cochrane Training. Cochrane handbook for systematic reviews of interventions. Version 6.5. 2024. https:\/\/training.cochrane.org\/handbook\/current. Accessed 27 Sept 2024."},{"key":"3656_CR29","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.jclinepi.2016.01.021","volume":"75","author":"J McGowan","year":"2016","unstructured":"McGowan J, Sampson M, Salzwedel DM, et al. PRESS peer review of electronic search strategies: 2015 guideline statement. J Clin Epidemiol. 2016;75:40\u20136. https:\/\/doi.org\/10.1016\/j.jclinepi.2016.01.021.","journal-title":"J Clin Epidemiol"},{"issue":"12","key":"3656_CR30","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.1111\/j.1398-9995.2006.01197.x","volume":"61","author":"M Bas","year":"2006","unstructured":"Bas M, Bier H, Greve J, Kojda G, Hoffmann TK. Novel pharmacotherapy of acute hereditary angioedema with bradykinin B2-receptor antagonist icatibant. Allergy. 2006;61(12):1490\u20132. https:\/\/doi.org\/10.1111\/j.1398-9995.2006.01197.x.","journal-title":"Allergy"},{"issue":"11","key":"3656_CR31","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1111\/all.12244","volume":"68","author":"M Ba\u015f","year":"2013","unstructured":"Ba\u015f M, Greve J, Hoffmann TK, et al. Repeat treatment with icatibant for multiple hereditary angioedema attacks: FAST-2 open-label study. Allergy. 2013;68(11):1452\u20139.","journal-title":"Allergy"},{"issue":"6","key":"3656_CR32","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1111\/j.1537-2995.2007.01239.x","volume":"47","author":"G Choi","year":"2007","unstructured":"Choi G, Soeters MR, Farkas H, et al. Recombinant human C1-inhibitor in the treatment of acute angioedema attacks. Transfusion. 2007;47(6):1028\u201332. https:\/\/doi.org\/10.1111\/j.1537-2995.2007.01239.x.","journal-title":"Transfusion"},{"issue":"12","key":"3656_CR33","doi-asserted-by":"publisher","first-page":"1604","DOI":"10.1111\/j.1398-9995.2011.02702.x","volume":"66","author":"T Craig","year":"2011","unstructured":"Craig T, Bewtra AK, Bahna S, et al. C1 esterase inhibitor concentrate in 1085\u00a0hereditary angioedema attacks\u2013final results of the IMPACT 2 study. Allergy. 2011;66(12):1604\u201311.","journal-title":"Allergy"},{"issue":"4","key":"3656_CR34","doi-asserted-by":"publisher","first-page":"354","DOI":"10.2500\/aap.2012.33.3589","volume":"33","author":"TJ Craig","year":"2012","unstructured":"Craig TJ, Bewtra AK, Hurewitz D, et al. Treatment response after repeated administration of C1 esterase inhibitor for successive acute hereditary angioedema attacks. Allergy Asthma Proc. 2012;33(4):354\u201361.","journal-title":"Allergy Asthma Proc"},{"issue":"6","key":"3656_CR35","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1007\/s10875-010-9442-1","volume":"30","author":"TJ Craig","year":"2010","unstructured":"Craig TJ, Wasserman RL, Levy RJ, et al. Prospective study of rapid relief provided by C1 esterase inhibitor in emergency treatment of acute laryngeal attacks in hereditary angioedema. J Clin Immunol. 2010;30(6):823\u20139.","journal-title":"J Clin Immunol"},{"issue":"6","key":"3656_CR36","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1016\/j.jaip.2017.04.010","volume":"5","author":"H Farkas","year":"2017","unstructured":"Farkas H, Reshef A, Aberer W, et al. Treatment effect and safety of icatibant in pediatric patients with hereditary angioedema. J Allergy Clin Immunol Pract. 2017;5(6):1671-78.e2.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"5","key":"3656_CR37","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1016\/j.anai.2016.08.025","volume":"117","author":"H Farkas","year":"2016","unstructured":"Farkas H, Varga L, Moldovan D, et al. Assessment of inhibitory antibodies in patients with hereditary angioedema treated with plasma-derived C1 inhibitor. Ann Allergy Asthma Immunol. 2016;117(5):508\u201313.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"6","key":"3656_CR38","doi-asserted-by":"publisher","first-page":"406","DOI":"10.18176\/jiaci.1009","volume":"34","author":"M Lluncor-Salazar","year":"2024","unstructured":"Lluncor-Salazar M, Phillips-Angles E, Pedrosa M, et al. Determinants of disease activity in adults with hereditary angioedema due to C1-esterase inhibitor deficiency. J Investig Allergol Clin Immunol. 2024;34(6):406\u20139.","journal-title":"J Investig Allergol Clin Immunol"},{"issue":"6","key":"3656_CR39","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1111\/j.1365-2222.2012.03984.x","volume":"42","author":"D Moldovan","year":"2012","unstructured":"Moldovan D, Reshef A, Fabiani J, et al. Efficacy and safety of recombinant human C1-inhibitor for the treatment of attacks of hereditary angioedema: European open-label extension study. Clin Exp Allergy. 2012;42(6):929\u201335.","journal-title":"Clin Exp Allergy"},{"issue":"2","key":"3656_CR40","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1111\/cei.12358","volume":"177","author":"A Malbr\u00e1n","year":"2014","unstructured":"Malbr\u00e1n A, Riedl M, Ritchie B, et al. Repeat treatment of acute hereditary angioedema attacks with open-label icatibant in the FAST-1 trial. Clin Exp Immunol. 2014;177(2):544\u201353.","journal-title":"Clin Exp Immunol"},{"key":"3656_CR41","first-page":"55","volume":"15","author":"JPM Paris","year":"1980","unstructured":"Paris JPM, Brecy H. Pharmacochemical approach to a biochemical disease: search for synthetic inhibitors of C(1) esterase. Eur J Med Chem. 1980;15:55\u201362.","journal-title":"Eur J Med Chem"},{"issue":"5","key":"3656_CR42","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1111\/pai.13065","volume":"30","author":"A Reshef","year":"2019","unstructured":"Reshef A, Grivcheva-Panovska V, Kessel A, et al. Recombinant human C1 esterase inhibitor treatment for hereditary angioedema attacks in children. Pediatr Allergy Immunol. 2019;30(5):562\u20138. https:\/\/doi.org\/10.1111\/pai.13065.","journal-title":"Pediatr Allergy Immunol"},{"issue":"1","key":"3656_CR43","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.anai.2010.10.012","volume":"106","author":"RL Wasserman","year":"2011","unstructured":"Wasserman RL, Levy RJ, Bewtra AK, et al. Prospective study of C1 esterase inhibitor in the treatment of successive acute abdominal and facial hereditary angioedema attacks. Ann Allergy Asthma Immunol. 2011;106(1):62\u20138.","journal-title":"Ann Allergy Asthma Immunol"},{"key":"3656_CR44","unstructured":"Open-label patient continuation of DX-88 (ecallantide) for acute hereditary angioedema attacks. National Library of Medicine (US). ClinicalTrials.gov identifier: NCT00456508. Updated June 8, 2021. https:\/\/clinicaltrials.gov\/study\/NCT00456508. Accessed 6 Aug 2025."},{"issue":"3","key":"3656_CR45","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.jaip.2014.12.013","volume":"3","author":"HH Li","year":"2015","unstructured":"Li HH, Moldovan D, Bernstein JA, et al. Recombinant human-C1 inhibitor is effective and safe for repeat hereditary angioedema attacks. J Allergy Clin Immunol Pract. 2015;3(3):417\u201323.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"4","key":"3656_CR46","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.anai.2013.02.007","volume":"110","author":"MA Riedl","year":"2013","unstructured":"Riedl MA, Levy RJ, Suez D, et al. Efficacy and safety of recombinant C1 inhibitor for the treatment of hereditary angioedema attacks: a North American open-label study. Ann Allergy Asthma Immunol. 2013;110(4):295\u20139.","journal-title":"Ann Allergy Asthma Immunol"},{"key":"3656_CR47","unstructured":"Open-label, multicenter study to evaluate safety, local tolerability, convenience, and efficacy of a self-administered subcutaneous formulation of icantibant for the treatment of acute attacks of hereditary angioedema. https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2008-000071-25\/results. Accessed 17 Mar 2025."},{"issue":"3","key":"3656_CR48","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/j.anai.2020.05.015","volume":"125","author":"JA Bernstein","year":"2020","unstructured":"Bernstein JA, Schwartz L, Yang W, et al. Long-term safety and efficacy of subcutaneous C1-inhibitor in older patients with hereditary angioedema. Ann Allergy Asthma Immunol. 2020;125(3):334-40. e1.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"6","key":"3656_CR49","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.1016\/j.jaip.2019.01.054","volume":"7","author":"T Craig","year":"2019","unstructured":"Craig T, Zuraw B, Longhurst H, et al. Long-term outcomes with subcutaneous C1-inhibitor replacement therapy for prevention of hereditary angioedema attacks. J Allergy Clin Immunol Pract. 2019;7(6):1793-802.e2. https:\/\/doi.org\/10.1016\/j.jaip.2019.01.054.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"5","key":"3656_CR50","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1111\/jcpt.12997","volume":"44","author":"J Jeon","year":"2019","unstructured":"Jeon J, Lee YJ, Lee SY. Effect of icatibant on angiotensin-converting enzyme inhibitor-induced angioedema: a meta-analysis of randomized controlled trials. J Clin Pharm Ther. 2019;44(5):685\u201392. https:\/\/doi.org\/10.1111\/jcpt.12997.","journal-title":"J Clin Pharm Ther"},{"issue":"3","key":"3656_CR51","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1089\/ped.2020.1143","volume":"33","author":"D Levy","year":"2020","unstructured":"Levy D, Caballero T, Hussain I, et al. Long-term efficacy of subcutaneous C1 inhibitor in pediatric patients with hereditary angioedema. Pediatr Allergy Immunol Pulmonol. 2020;33(3):136\u201341. https:\/\/doi.org\/10.1089\/ped.2020.1143.","journal-title":"Pediatr Allergy Immunol Pulmonol"},{"issue":"1","key":"3656_CR52","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s13223-020-0409-3","volume":"16","author":"DS Levy","year":"2020","unstructured":"Levy DS, Farkas H, Riedl MA, et al. Long-term efficacy and safety of subcutaneous C1-inhibitor in women with hereditary angioedema: subgroup analysis from an open-label extension of a phase\u00a03 trial. Allergy Asthma Clin Immunol. 2020;16(1):8.","journal-title":"Allergy Asthma Clin Immunol"},{"issue":"1","key":"3656_CR53","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s13023-020-01658-4","volume":"16","author":"WR Lumry","year":"2021","unstructured":"Lumry WR, Zuraw B, Cicardi M, et al. Long-term health-related quality of life in patients treated with subcutaneous C1-inhibitor replacement therapy for the prevention of hereditary angioedema attacks: findings from the COMPACT open-label extension study. Orphanet J Rare Dis. 2021;16(1):86. https:\/\/doi.org\/10.1186\/s13023-020-01658-4.","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"3656_CR54","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1111\/all.15861","volume":"79","author":"M Magerl","year":"2024","unstructured":"Magerl M, Schiffhorst G, Fanter L, et al. Patient-level indirect treatment comparison of lanadelumab versus pdC1-INH i.v. in hereditary angioedema patients: PATCH study. Allergy. 2024;79(1):215\u201324. https:\/\/doi.org\/10.1111\/all.15861.","journal-title":"Allergy"},{"issue":"6","key":"3656_CR55","doi-asserted-by":"publisher","first-page":"489","DOI":"10.2500\/aap.2016.37.4006","volume":"37","author":"MA Riedl","year":"2016","unstructured":"Riedl MA, Lumry WR, Li HH, et al. Subcutaneous administration of human C1 inhibitor with recombinant human hyaluronidase in patients with hereditary angioedema. Allergy Asthma Proc. 2016;37(6):489\u2013500. https:\/\/doi.org\/10.2500\/aap.2016.37.4006.","journal-title":"Allergy Asthma Proc"},{"issue":"9","key":"3656_CR56","doi-asserted-by":"publisher","first-page":"938. e1","DOI":"10.1016\/j.amjmed.2012.02.020","volume":"125","author":"BL Zuraw","year":"2012","unstructured":"Zuraw BL, Kalfus I. Safety and efficacy of prophylactic nanofiltered C1-inhibitor in hereditary angioedema. Am J Med. 2012;125(9):938.e1\u20137.","journal-title":"Am J Med"},{"key":"3656_CR57","unstructured":"An open-label, randomized study to evaluate the long-term clinical safety and efficacy of subcutaneous administration of human plasma-derived C1-esterase inhibitor in the prophylactic treatment of hereditary angioedema. ClinicalTrials.gov identifier: NCT02316353. Updated November 14, 2018. https:\/\/clinicaltrials.gov\/study\/NCT02316353. Accessed 6 Aug 2025."},{"key":"3656_CR58","unstructured":"A phase 3, randomized, double-blind, placebo-controlled, two-period, three-sequence, partial crossover study to evaluate the efficacy and safety of subcutaneous administration of 2000 IU of C1 esterase inhibitor [human] liquid for injection for the prevention of angioedema attacks in adolescents and adults with hereditary angioedema. ClinicalTrials.gov identifier: NCT02584959. Updated June 8, 2021. https:\/\/clinicaltrials.gov\/study\/NCT02584959. Accessed 6 Aug 2025."},{"issue":"3","key":"3656_CR59","doi-asserted-by":"publisher","first-page":"202","DOI":"10.2500\/aap.2022.43.220016","volume":"43","author":"T Craig","year":"2022","unstructured":"Craig T, Feuersenger H, Pragst I, Dang J. Prophylactic therapy with subcutaneous C1-inhibitor is associated with sustained symptom control in patients with hereditary angioedema. Allergy Asthma Proc. 2022;43(3):202\u20138. https:\/\/doi.org\/10.2500\/aap.2022.43.220016.","journal-title":"Allergy Asthma Proc"},{"issue":"6","key":"3656_CR60","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1046\/j.1537-2995.1998.38698326333.x","volume":"38","author":"M Kunschak","year":"1998","unstructured":"Kunschak M, Engl W, Maritsch F, et al. A randomized, controlled trial to study the efficacy and safety of C1 inhibitor concentrate in treating hereditary angioedema. Transfusion. 1998;38(6):540\u20139. https:\/\/doi.org\/10.1046\/j.1537-2995.1998.38698326333.x.","journal-title":"Transfusion"},{"issue":"5","key":"3656_CR61","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1016\/j.jaip.2017.12.039","volume":"6","author":"WR Lumry","year":"2018","unstructured":"Lumry WR, Craig T, Zuraw B, et al. Health-related quality of life with subcutaneous C1-inhibitor for prevention of attacks of hereditary angioedema. J Allergy Clin Immunol Pract. 2018;6(5):1733-41.e3.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"25","key":"3656_CR62","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1056\/NEJM199606203342503","volume":"334","author":"AT Waytes","year":"1996","unstructured":"Waytes AT, Rosen FS, Frank MM. Treatment of hereditary angioedema with a vapor-heated C1 inhibitor concentrate. N Engl J Med. 1996;334(25):1630\u20134.","journal-title":"N Engl J Med"},{"key":"3656_CR63","unstructured":"LEVP2005-1\/Part A: A double-blind, placebo-controlled, clinical study to investigate the efficacy and safety of purified C1 esterase inhibitor (human) for the treatment of HAE in acute attacks. ClinicalTrials.gov identifier: NCT00289211. Updated June 11, 2021. https:\/\/clinicaltrials.gov\/study\/NCT00289211. Accessed 6 Aug 2025."},{"key":"3656_CR64","unstructured":"LEVP2006-1 CHANGE 2 Trial (C1-inhibitor in hereditary angioedema nanofiltration generation evaluating efficacy): open-label safety\/efficacy repeat exposure study of C1INH-nf (human) in the treatment of acute HAE attacks. ClinicalTrials.gov identifier: NCT00438815. Updated June 8, 2021. https:\/\/clinicaltrials.gov\/study\/NCT00438815. Accessed 6 Aug 2025."},{"key":"3656_CR65","unstructured":"LEVP2005-1\/Part B: A double-blind, placebo-controlled, clinical study to investigate the efficacy and safety of purified C1 esterase inhibitor (human) as prophylactic treatment to prevent HAE attacks. ClinicalTrials.gov identifier: NCT01005888. Updated June 11, 2021. https:\/\/clinicaltrials.gov\/study\/NCT01005888. Accessed 6 Aug 2025."},{"issue":"6","key":"3656_CR66","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1056\/NEJMoa0805538","volume":"363","author":"BL Zuraw","year":"2010","unstructured":"Zuraw BL, Busse PJ, White M, et al. Nanofiltered C1 inhibitor concentrate for treatment of hereditary angioedema. N Engl J Med. 2010;363(6):513\u201322. https:\/\/doi.org\/10.1056\/NEJMoa0805538.","journal-title":"N Engl J Med"},{"issue":"6","key":"3656_CR67","doi-asserted-by":"publisher","first-page":"517","DOI":"10.2500\/ajra.2013.27.3973","volume":"27","author":"MA Riedl","year":"2013","unstructured":"Riedl MA, Lumry WR, Li HH, et al. Nanofiltered C1 esterase inhibitor for treatment of laryngeal attacks in patients with hereditary angioedema. Am J Rhinol Allergy. 2013;27(6):517\u201321.","journal-title":"Am J Rhinol Allergy"},{"issue":"1","key":"3656_CR68","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.anai.2011.10.017","volume":"108","author":"MA Riedl","year":"2012","unstructured":"Riedl MA, Hurewitz DS, Levy R, et al. Nanofiltered C1 esterase inhibitor (human) for the treatment of acute attacks of hereditary angioedema: an open-label trial. Ann Allergy Asthma Immunol. 2012;108(1):49\u201353.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"4","key":"3656_CR69","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1016\/j.jemermed.2015.11.008","volume":"50","author":"K Bork","year":"2016","unstructured":"Bork K, Bernstein JA, Machnig T, Craig TJ. Efficacy of different medical therapies for the treatment of acute laryngeal attacks of hereditary angioedema due to C1-esterase inhibitor deficiency. J Emerg Med. 2016;50(4):567-80. e1.","journal-title":"J Emerg Med"},{"issue":"7","key":"3656_CR70","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1080\/17512433.2020.1776110","volume":"13","author":"K Burnham","year":"2020","unstructured":"Burnham K, Reinert JP. Thromboembolic risk of C1 esterase inhibitors: a systematic review on current evidence. Expert Rev Clin Pharmacol. 2020;13(7):779\u201386. https:\/\/doi.org\/10.1080\/17512433.2020.1776110.","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"9","key":"3656_CR71","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1056\/NEJM198008283030918","volume":"303","author":"R Chapman","year":"1980","unstructured":"Chapman R. C1-inhibitor concentrate for treatment of hereditary angioedema. N Engl J Med. 1980;303(9):526.","journal-title":"N Engl J Med"},{"issue":"2","key":"3656_CR72","first-page":"95","volume":"81","author":"P Kawalec","year":"2013","unstructured":"Kawalec P, Holko P, Paszulewicz A, Obtu\u0142owicz K. Administration of conestat alfa, human C1 esterase inhibitor and icatibant in the treatment of acute angioedema attacks in adults with hereditary angioedema due to C1 esterase inhibitor deficiency: treatment comparison based on systematic review results. Pneumonol Alergol Pol. 2013;81(2):95\u2013104.","journal-title":"Pneumonol Alergol Pol"},{"issue":"1-3","key":"3656_CR73","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s12016-024-09006-1","volume":"67","author":"HJ Longhurst","year":"2024","unstructured":"Longhurst HJ, Cancian M, Grivcheva-Panovska V, et al. Hereditary angioedema attacks in patients receiving long-term prophylaxis: a systematic review. Clin Rev Allergy Immunol. 2024;67(1\u20133):83\u201395. https:\/\/doi.org\/10.1007\/s12016-024-09006-1.","journal-title":"Clin Rev Allergy Immunol"},{"key":"3656_CR74","volume":"8","author":"S Nicola","year":"2019","unstructured":"Nicola S, Rolla G, Brussino L. Breakthroughs in hereditary angioedema management: a systematic review of approved drugs and those under research. Drugs Context. 2019;8:212605.","journal-title":"Drugs Context"},{"issue":"5","key":"3656_CR75","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/BF03261889","volume":"26","author":"GL Plosker","year":"2012","unstructured":"Plosker GL. Recombinant human C1 inhibitor (conestat alfa) in the treatment of angioedema attacks in hereditary angioedema. BioDrugs. 2012;26(5):315\u201323.","journal-title":"BioDrugs"},{"key":"3656_CR76","doi-asserted-by":"crossref","unstructured":"New drugs: icatibant. Australian Prescriber. 2010;33(6):195.","DOI":"10.18773\/austprescr.2010.092"},{"key":"3656_CR77","unstructured":"Ayg\u00f6ren-P\u00fcrs\u00fcn E, Zanichelli A, Cohn DM, et al. Efficacy and safety of the oral plasma kallikrein inhibitor sebetralstat (KVD900) in adolescent and adult patients with hereditary angioedema: phase\u00a03 trial design. Presented at: European Academy of Allergy and Clinical Immunology (EAACI) Hybrid Congress: July 1\u20133, 2022; Prague, Czech Republic."},{"key":"3656_CR78","unstructured":"Lumry WR, Aygoren-Pursun E, Zanichelli A, et al. Phase\u00a03 trial design for KVD900, a novel investigational oral plasma kallikrein inhibitor for the on-demand treatment of hereditary angioedema attacks. Presented at Euorpean Academy of Allergy and Clinical Immunology (EAACI) Congress; July 1\u20133, 2022; Prague, Czech Republic. 2022."},{"key":"3656_CR79","unstructured":"Subcutaneous treatment with icatibant for acute attacks of hereditary angioedema (HAE) (FAST2). ClinicalTrials.gov identifier: NCT00500656. https:\/\/clinicaltrials.gov\/study\/NCT00500656?term=NCT00500656&rank=1. Accessed 16 Mar 2025."},{"issue":"5","key":"3656_CR80","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1111\/all.12587","volume":"70","author":"A Reshef","year":"2015","unstructured":"Reshef A, Zanichelli A, Longhurst H, Relan A, Hack CE. Elevated D-dimers in attacks of hereditary angioedema are not associated with increased thrombotic risk. Allergy. 2015;70(5):506\u201313. https:\/\/doi.org\/10.1111\/all.12587.","journal-title":"Allergy"},{"issue":"6","key":"3656_CR81","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1016\/j.jaci.2007.02.012","volume":"119","author":"K Bork","year":"2007","unstructured":"Bork K, Frank J, Grundt B, et al. Treatment of acute edema attacks in hereditary angioedema with a bradykinin receptor-2 antagonist (icatibant). J Allergy Clin Immunol. 2007;119(6):1497\u2013503. https:\/\/doi.org\/10.1016\/j.jaci.2007.02.012.","journal-title":"J Allergy Clin Immunol"},{"key":"3656_CR82","doi-asserted-by":"crossref","unstructured":"Li HH, Magerl M, Craig T, et al. Indirect treatment comparison of oral sebetralstat and intravenous rhC1-INH as on-demand treatments for hereditary angioedema. Presented at: the American College of Allergy, Asthma & Immunology 2024 Annual Scientific Meeting; October 24\u201328, 2024; Boston, MA.","DOI":"10.1016\/j.anai.2024.08.114"},{"key":"3656_CR83","unstructured":"Ayg\u00f6ren-P\u00fcrs\u00fcn E, Zanichelli A, Cohn DM, et al. Sebetralstat, investigational oral on-demand treatment for HAE: KONFIDENT trial design. Presented at: 25th Annual Scientific Session of the Intermountain West Allergy Association (IWAA); August 3\u20135, 2023; Park City, Utah."},{"key":"3656_CR84","unstructured":"Randomised, double blind, controlled, parallel group, multicentre study of a subcutaneous formulation of icatibant vs. oral tranexamic acid for the treatment of hereditary angioedema (HAE). https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2004-001540-71\/results. Accessed 17 Mar 2025."},{"key":"3656_CR85","unstructured":"US Food and Drug Administration. Approval letter: Firazyr (icatibant). August 24, 2011. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2011\/022150Orig1s000Approv.pdf. Accessed 17 Mar 2025."},{"key":"3656_CR86","unstructured":"US Food and Drug Admnistration. Medical review: Firazyr (icatibant). Review completion date July 27, 2011. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2011\/022150Orig1s000MedR.pdf. Accessed 17 Mar 2025."},{"key":"3656_CR87","unstructured":"US Food and Drug Administration. Statistical review: Firazyr (icatibant). Received February 25, 2011. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2011\/022150Orig1s000StatR.pdf. Accessed 17 Mar 2025."},{"key":"3656_CR88","unstructured":"US Food and Drug Administration. Summary review: Firazyr (icatibant). August 24, 2011. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2011\/022150Orig1s000SumR.pdf. Accessed 17 Mar 2025."},{"key":"3656_CR89","unstructured":"European Medicines Agency. Summary of product characteristics: Firazyr (icatibant). https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/firazyr#:~:text=This%20is%20a%20summary%20of%20the%20European%20public,provide%20practical%20advice%20on%20how%20to%20use%20Firazyr. Accessed 17 Mar 2025."},{"issue":"6","key":"3656_CR90","doi-asserted-by":"publisher","first-page":"456","DOI":"10.2500\/aap.2017.38.4088","volume":"38","author":"HH Li","year":"2017","unstructured":"Li HH, Reshef A, Baker JW, Harper JR, Relan A. Efficacy of recombinant human C1 esterase inhibitor for the treatment of severe hereditary angioedema attacks. Allergy Asthma Proc. 2017;38(6):456\u201361.","journal-title":"Allergy Asthma Proc"},{"key":"3656_CR91","unstructured":"Efficacy, safety and immunogenicity study of recombinant human C1 inhibitor for the treatment of acute HAE attacks. ClinicalTrials.gov identifier: NCT01188564. https:\/\/clinicaltrials.gov\/study\/NCT01188564?term=NCT01188564&rank=1. Accessed 16 Mar 2025."},{"issue":"5","key":"3656_CR92","doi-asserted-by":"publisher","first-page":"359","DOI":"10.2500\/aap.2018.39.4151","volume":"39","author":"JW Baker","year":"2018","unstructured":"Baker JW, Bernstein JA, Harper JR, Relan A, Riedl MA. Efficacy of recombinant human C1 esterase inhibitor across anatomic locations in acute hereditary angioedema attacks. Allergy Asthma Proc. 2018;39(5):359\u201364.","journal-title":"Allergy Asthma Proc"},{"issue":"6","key":"3656_CR93","doi-asserted-by":"publisher","first-page":"462","DOI":"10.2500\/aap.2017.38.4090","volume":"38","author":"MA Riedl","year":"2017","unstructured":"Riedl MA, Li HH, Cicardi M, Harper JR, Relan A. Recombinant human C1 esterase inhibitor for acute hereditary angioedema attacks with upper airway involvement. Allergy Asthma Proc. 2017;38(6):462\u20136.","journal-title":"Allergy Asthma Proc"},{"issue":"4","key":"3656_CR94","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1016\/j.anai.2017.01.029","volume":"118","author":"JA Bernstein","year":"2017","unstructured":"Bernstein JA, Relan A, Harper JR, Riedl M. Sustained response of recombinant human C1 esterase inhibitor for acute treatment of hereditary angioedema attacks. Ann Allergy Asthma Immunol. 2017;118(4):452\u20135.","journal-title":"Ann Allergy Asthma Immunol"},{"key":"3656_CR95","unstructured":"US Food and Drug Administration. Approval letter: RUCONEST (C1 esterase inhibitor [recombinant]). July 16, 2014. https:\/\/www.fda.gov\/vaccines-blood-biologics\/approved-blood-products\/ruconest. Accessed 17 Mar 2025."},{"key":"3656_CR96","unstructured":"US Food and Drug Administration. Clinical review memo: RUCONEST (recombinant C1 esterase inhibitor). STN 125495\/0). https:\/\/www.fda.gov\/vaccines-blood-biologics\/approved-blood-products\/ruconest. Accessed 17 Mar 2025."},{"key":"3656_CR97","unstructured":"US Food and Drug Administraion. Statistical review: RUCONEST (C1 esterase inhibitor [recombinant]). May\u00a016, 2014. https:\/\/www.fda.gov\/vaccines-blood-biologics\/approved-blood-products\/ruconest. Accessed 17 Mar 2025."},{"key":"3656_CR98","unstructured":"US Food and Drug Administration. Summary basis for regulatory action: RUCONEST (C1 esterase inhibitor [recombinant]). June 02, 2024. https:\/\/www.fda.gov\/vaccines-blood-biologics\/approved-blood-products\/ruconest. Accessed 17 Mar 2025."},{"key":"3656_CR99","unstructured":"Efficacy study of DX-88 (ecallantide) to treat acute attacks of hereditary angioedema (HAE). ClinicalTrials.gov identifier: NCT00457015. https:\/\/clinicaltrials.gov\/study\/NCT00457015?term=NCT00457015&rank=1. Accessed 16 Mar 2025."},{"issue":"2","key":"3656_CR100","doi-asserted-by":"publisher","first-page":"178","DOI":"10.2500\/aap.2012.33.3528","volume":"33","author":"AJ MacGinnitie","year":"2012","unstructured":"MacGinnitie AJ, Campion M, Stolz LE, Pullman WE. Ecallantide for treatment of acute hereditary angioedema attacks: analysis of efficacy by patient characteristics. Allergy Asthma Proc. 2012;33(2):178\u201385.","journal-title":"Allergy Asthma Proc"},{"issue":"1","key":"3656_CR101","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1586\/eci.11.81","volume":"8","author":"LE Stolz","year":"2012","unstructured":"Stolz LE, Sheffer AL. Prospective, double-blind, placebo-controlled trials of ecallantide for acute attacks of hereditary angioedema. Expert Rev Clin Immunol. 2012;8(1):25\u201332.","journal-title":"Expert Rev Clin Immunol"},{"issue":"6","key":"3656_CR102","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1016\/j.anai.2010.09.005","volume":"105","author":"M Riedl","year":"2010","unstructured":"Riedl M, Campion M, Horn PT, Pullman WE. Response time for ecallantide treatment of acute hereditary angioedema attacks. Ann Allergy Asthma Immunol. 2010;105(6):430-36. e2.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"9","key":"3656_CR103","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1111\/j.1398-9995.2012.02864.x","volume":"67","author":"J Bernstein","year":"2012","unstructured":"Bernstein J, Shea E, Koester J, Iarrobino R, Pullman W. Assessment of rebound and relapse following ecallantide treatment for acute attacks of hereditary angioedema. Allergy. 2012;67(9):1173\u201380.","journal-title":"Allergy"},{"issue":"1","key":"3656_CR104","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.jaci.2011.03.006","volume":"128","author":"AL Sheffer","year":"2011","unstructured":"Sheffer AL, Campion M, Levy RJ, et al. Ecallantide (DX-88) for acute hereditary angioedema attacks: integrated analysis of 2 double-blind, phase\u00a03 studies. J Allergy Clin Immunol. 2011;128(1):153-59. e4.","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"3656_CR105","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.anai.2012.12.007","volume":"110","author":"AL Sheffer","year":"2013","unstructured":"Sheffer AL, MacGinnitie AJ, Campion M, Stolz LE, Pullman WE. Outcomes after ecallantide treatment of laryngeal hereditary angioedema attacks. Ann Allergy Asthma Immunol. 2013;110(3):184-88. e2.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"2","key":"3656_CR106","doi-asserted-by":"publisher","first-page":"e490","DOI":"10.1542\/peds.2013-0646","volume":"132","author":"AJ MacGinnitie","year":"2013","unstructured":"MacGinnitie AJ, Davis-Lorton M, Stolz LE, Tachdjian R. Use of ecallantide in pediatric hereditary angioedema. Pediatrics. 2013;132(2):e490\u20137.","journal-title":"Pediatrics"},{"issue":"1","key":"3656_CR107","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/1471-230X-14-71","volume":"14","author":"E Rubinstein","year":"2014","unstructured":"Rubinstein E, Stolz LE, Sheffer AL, Stevens C, Bousvaros A. Abdominal attacks and treatment in hereditary angioedema with C1-inhibitor deficiency. BMC Gastroenterol. 2014;14(1):71.","journal-title":"BMC Gastroenterol"},{"key":"3656_CR108","unstructured":"US Food and Drug Administration. Approval letter: Kalbitor (ecallantide). December 1, 2009. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/appletter\/2009\/125277s000ltr.pdf. Accessed 17 Mar 2025."},{"key":"3656_CR109","unstructured":"US Food and Drug Administration. Clinical review: Kalbitor (ecallantide). October 22, 2009. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2009\/125277s000MedrR_P1.pdf. Accessed 17 Mar 2025."},{"key":"3656_CR110","unstructured":"US Food and Drug Administration. Statistical review: Kalbitor (ecallantide). June 1, 2009. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2009\/125277s000StatR.pdf. Accessed 17 Mar 2025."},{"key":"3656_CR111","unstructured":"US Food and Drug Administration. Summary review: Kalbitor (ecallantide). December 1, 2009. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2009\/125277s000SumR.pdf. Accessed 17 Mar 2025."},{"key":"3656_CR112","unstructured":"Efficacy and safety study of DX-88 to treat acute attacks of hereditary angioedema (HAE). ClinicalTrials.gov identifier: NCT00262080. https:\/\/clinicaltrials.gov\/study\/NCT00262080?term=NCT00262080&rank=1. Accessed 16 Mar 2025."},{"key":"3656_CR113","unstructured":"EDEMA3: Evaluation of DX-88\u2019s effects in mitigating angioedema. A double-blind, placebo-controlled study followed by a repeat dosing phase to assess the efficacy and safety of DX-88 (recombinant plasma kallikrein inhibitor) for the treatment of acute attacks of hereditary angioedema. EudraCT Number: 2005-003819-71. https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2005-003819-71\/GB. Accessed 17 Mar 2025."},{"issue":"2","key":"3656_CR114","doi-asserted-by":"publisher","first-page":"155","DOI":"10.2500\/aap.2013.34.3653","volume":"34","author":"WR Lumry","year":"2013","unstructured":"Lumry WR, Bernstein JA, Li HH, et al. Efficacy and safety of ecallantide in treatment of recurrent attacks of hereditary angioedema: open-label continuation study. Allergy Asthma Proc. 2013;34(2):155\u201361.","journal-title":"Allergy Asthma Proc"},{"key":"3656_CR115","unstructured":"A phase\u00a0III randomized double-blind, placebo-controlled multicenter study of icatibant for subcutaneous injection in patients with acute attacks of hereditary angioedema (HAE). EudraCT Number: 2009-015606-19. https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=EUCTR2009-015606-19-HU. Accessed 17 Mar 2025."},{"key":"3656_CR116","unstructured":"A study of icatibant in patients with acute attacks of hereditary angioedema (FAST-3). 2021. ClinicalTrials.gov identifier: NCT00912093. https:\/\/clinicaltrials.gov\/search?term=NCT00912093. Accessed 16 Mar 2025."},{"issue":"8","key":"3656_CR117","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1586\/eci.12.67","volume":"8","author":"M Bas","year":"2012","unstructured":"Bas M. Clinical efficacy of icatibant in the treatment of acute hereditary angioedema during the FAST-3 trial. Expert Rev Clin Immunol. 2012;8(8):707\u201317.","journal-title":"Expert Rev Clin Immunol"},{"issue":"9","key":"3656_CR118","doi-asserted-by":"publisher","DOI":"10.1002\/clt2.12288","volume":"13","author":"DM Cohn","year":"2023","unstructured":"Cohn DM, Ayg\u00f6ren-P\u00fcrs\u00fcn E, Bernstein JA, et al. Evaluation of patient-reported outcome measures for on-demand treatment of hereditary angioedema attacks and design of KONFIDENT, a phase\u00a03 trial of sebetralstat. Clin Transl Allergy. 2023;13(9):e12288.","journal-title":"Clin Transl Allergy"},{"issue":"6","key":"3656_CR119","doi-asserted-by":"publisher","first-page":"S29","DOI":"10.1016\/j.anai.2024.08.115","volume":"133","author":"T Craig","year":"2024","unstructured":"Craig T, Bernstein J, Longhurst H, et al. Correlation of time to treatment with attack duration in the sebetralstat KONFIDENT phase\u00a03 trial. Ann Allergy Asthma Immunol. 2024;133(6):S29.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"6","key":"3656_CR120","doi-asserted-by":"publisher","first-page":"S33","DOI":"10.1016\/j.anai.2024.08.128","volume":"133","author":"E Ayg\u00f6ren-Pursun","year":"2024","unstructured":"Ayg\u00f6ren-Pursun E, Bernstein J, Lumry W, et al. On-demand treatment of laryngeal hereditary angioedema attacks with sebetralstat: pooled analysis from KONFIDENT and KONFIDENT-S. Ann Allergy Asthma Immunol. 2024;133(6):S33.","journal-title":"Ann Allergy Asthma Immunol"},{"key":"3656_CR121","unstructured":"Zanichelli A, Ayg\u00f6ren-Pursun E, Bernstein JA, et al. Phase\u00a03 KONFIDENT trial of oral sebetralstat for treatment of hereditary angioedema attacks: Analysis of the European and US patient subgroups. 2024. Presented at: ACARE Global Angioedema Forum 2024; October 4\u20135, 2024; Copenhagen, Denmark."},{"key":"3656_CR122","unstructured":"Maurer M, Cohn DM, Bernstein JA, et al. Impact of oral sebetralstat on anxiety associated with hereditary angioedema attacks in the phase\u00a03 KONFIDENT trial. Presented at: ACARE Global Angioedema Forum 2024; October 4\u20135, 2024; Copenhagen, Denmark."},{"key":"3656_CR123","unstructured":"Honda D, Hide M, Ohsawa I, et al. Sebetralstat KONFIDENT is the first phase\u00a03 on-demand HAE trial to include Japanese sites. Presented at: 123rd Annual Meeting of the Japanese Dermatological Association; June 6\u20139; Kyoto, Japan."},{"key":"3656_CR124","unstructured":"Cohn DM. Oral sebetralstat for on\u2013demand treatment of hereditary angioedema: Phase\u00a03 KONFIDENT trial results. Presented at: European Academy of Allergy and Clinical Immunology (EAACI); May\u00a013-June 3, 2024; Valencia, Spain."},{"key":"3656_CR125","unstructured":"Soteres DF, Riedl MA, Lumry WR, et al. Sebetralstat for on-demand treatment of hereditary angioedema attacks: US subgroup analysis from the double-blind, placebo-controlled phase\u00a03 KONFIDENT trial. Presented at: Eastern Allergy Conference; May\u00a030-June 2, 2024; Palm Beach, FL."},{"key":"3656_CR126","unstructured":"Hide M, K. AP, Smith MD, Yea CM. Investigating on-demand use of oral sebetralstat in adults and adolescents with hereditary angioedema: multicenter, double-blind, randomized, placebo-controlled, phase\u00a03 KONFIDENT trial and open-label extension designs. 2023. Presented at: 72nd Annual Meeting of Japanese Society of Allergology; October 20\u201322, 2023; Tokyo, Japan."},{"key":"3656_CR127","unstructured":"Lumry WR, Ayg\u00f6ren-P\u00fcrs\u00fcn E, Zanichelli A, et al. KONFIDENT phase\u00a03 trial design for sebetralstat (KVD900), a novel investigational oral plasma kallikrein inhibitor for the on-demand treatment of hereditary angioedema attacks. Presented at: Eastern Allergy Conferences; June 2\u20135, 2022; Palm Beach, FL."},{"key":"3656_CR128","unstructured":"A phase\u00a0III, crossover trial evaluating the efficacy and safety of KVD900 for on-demand treatment of angioedema attacks in adolescent and adult patients with hereditary angioedema (HAE). ClinicalTrials.gov identifier: NCT05259917. https:\/\/clinicaltrials.gov\/study\/NCT05259917?term=NCT05259917&rank=1. Accessed 17 Mar 2025."},{"key":"3656_CR129","unstructured":"A randomized, double-blind, placebo-controlled, phase\u00a03, three-way crossover trial to evaluate the efficacy and safety of two dose levels of KVD900, an oral plasma kallikrein inhibitor, for on-demand treatment of angioedema attacks in adolescent and adult patients with hereditary angioedema type\u00a0I or II. EudraCT Number: 2021-001226-21. https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=EUCTR2021-001226-21-NL. Accessed 17 Mar 2025."},{"issue":"2","key":"3656_CR130","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2022.12.409","volume":"151","author":"J Bernstein","year":"2023","unstructured":"Bernstein J, Riedl M, Lumry W, et al. Treatment with sebetralstat reduces the cumulative symptom severity of hereditary angioedema attacks in a phase\u00a02 trial. J Allergy Clin Immunol. 2023;151(2):Suppl AB130.","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"3656_CR131","first-page":"563","volume":"43","author":"MD Smith","year":"2022","unstructured":"Smith MD, Duckworth EJ, Hampton SL, et al. Oral KVD900 provides rapid inhibition of plasma kallikrein and fast improvement in attack symptoms in patients with hereditary angioedema. Allergy Asthma Proc. 2022;43(6):563.","journal-title":"Allergy Asthma Proc"},{"issue":"6","key":"3656_CR132","volume":"43","author":"PK Audhya","year":"2022","unstructured":"Audhya PK, Smith MD, Williams P, Yea CM, Cohn DM. Agreement between improvements in patient global impression of change and other measures of improvement and attack resolution observed in a phase\u00a02 trial with sebetralstat (KVD900) in patients with hereditary angioedema. Allergy Asthma Proc. 2022;43(6):563.","journal-title":"Allergy Asthma Proc"},{"issue":"2","key":"3656_CR133","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2021.12.562","volume":"149","author":"U Audhya","year":"2022","unstructured":"Audhya U, Williams P, Yea C, Cohn D. Agreement of patient global impression of change with attack resolution or use of rescue medication in patients with hereditary angioedema. J Allergy Clin Immunol. 2022;149(2):Suppl AB170.","journal-title":"J Allergy Clin Immunol"},{"key":"3656_CR134","unstructured":"Duckworth E, Lee E, Murugesan N, et al. Oral sebetralstat (KVD900) provides rapid inhibition of the kallikrein kinin system in patients with hereditary angioedema. Presented at KININ2022; June 5\u20138, 2022; Annecy, France."},{"key":"3656_CR135","unstructured":"A phase\u00a0II, cross-over clinical trial evaluating the efficacy and safety of KVD900 in the on-demand treatment of angioedema attacks in adult subjects with hereditary angioedema type\u00a0I or II. ClinicalTrials.gov identifier: NCT04208412. https:\/\/clinicaltrials.gov\/study\/NCT04208412?term=NCT04208412&rank=1. Accessed 17 Mar 2025."},{"key":"3656_CR136","unstructured":"A randomized, double-blind, placebo-controlled, phase\u00a0II, cross-over clinical trial evaluating the efficacy and safety of KVD900, an oral plasma kallikrein inhibitor, in the on-demand treatment of angioedema attacks in adult subjects with hereditary angioedema type\u00a0I or II. EudraCT Number: 2018-004489-32. https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=EUCTR2018-004489-32-AT. Accessed 17 Mar 2025."},{"issue":"2","key":"3656_CR137","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2021.12.553","volume":"149","author":"E Duckworth","year":"2022","unstructured":"Duckworth E, Feener E, Yea C, et al. Rapid plasma kallikrein inhibition following oral KVD900 is associated with early symptom relief in patients with hereditary angioedema. J Allergy Clin Immunol. 2022;149(2):Suppl AB167.","journal-title":"J Allergy Clin Immunol"},{"key":"3656_CR138","unstructured":"Smith MD, Duckworth EJ, Hampton SL, et al. Oral sebetralstat (KVD900) provides rapid inhibition of plasma kallikrein and fast improvement in attack symptoms in patients with hereditary angioedema. Presented at: Eastern Allergy Conference; June 2\u20135, 2022; Palm Beach, FL, US."},{"key":"3656_CR139","unstructured":"Recombinant human C1 inhibitor for the treatment of acute attacks in patients with hereditary angioedema. ClinicalTrials.gov identifier: NCT00225147. https:\/\/clinicaltrials.gov\/study\/NCT00225147?term=NCT00225147&rank=1. Accessed 16 Mar 2025."},{"key":"3656_CR140","unstructured":"European Medicines Agency. RUCONEST ESopc. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/ruconest-epar-product-information_en.pdf. Accessed 17 Mar 2025."},{"key":"3656_CR141","unstructured":"Recombinant human C1 inhibitor for the treatment of acute attacks in patients with hereditary angioedema. ClinicalTrials.gov identifier: NCT00262301. https:\/\/clinicaltrials.gov\/study\/NCT00262301?term=NCT00262301&rank=1. Accessed 16 Mar 2025."},{"key":"3656_CR142","unstructured":"A randomized, placebo-controlled, double-blind phase\u00a0III study of the efficacy and safety of recombinant human C1 inhibitor for the treatment of acute attacks in patients with hereditary angioedema. EudraCT Number: 2005-000206-31. https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=EUCTR2005-000206-31-GB. Accessed 17 Mar 2025."},{"issue":"3","key":"3656_CR143","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.anai.2013.06.021","volume":"111","author":"TJ Craig","year":"2013","unstructured":"Craig TJ, Rojavin MA, Machnig T, Keinecke H-O, Bernstein JA. Effect of time to treatment on response to C1 esterase inhibitor concentrate for hereditary angioedema attacks. Ann Allergy Asthma Immunol. 2013;111(3):211\u20135.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"1","key":"3656_CR144","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1111\/pai.12024","volume":"24","author":"L Schneider","year":"2013","unstructured":"Schneider L, Hurewitz D, Wasserman R, et al. C1-INH concentrate for treatment of acute hereditary angioedema: a pediatric cohort from the IMPACT studies. Pediatr Allergy Immunol. 2013;24(1):54\u201360.","journal-title":"Pediatr Allergy Immunol"},{"key":"3656_CR145","unstructured":"Human C1 esterase inhibitor (C1-INH) in subjects with acute abdominal or facial hereditary angioedema (HAE) attacks. ClinicalTrials.gov identifier: NCT00168103. https:\/\/clinicaltrials.gov\/study\/NCT00168103?term=NCT00168103&rank=1. Accessed 16 Mar 2025."},{"key":"3656_CR146","unstructured":"Human pasteurized C1 esterase inhibitor concentrate (CE1145) in subjects with congenital C1-INH deficiency and acute abdominal or facial HAE attacks. EudraCT Number: 2004-001186-17. https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=EUCTR2004-001186-17-BG. Accessed 17 Mar 2025."},{"key":"3656_CR147","unstructured":"US Food and Drug Administration. Statistical review and evaluation: Berinert (C1 esterase inhibitor [human]). April 10, 2009. https:\/\/wayback.archive-it.org\/7993\/20170722071335\/https:\/www.fda.gov\/BiologicsBloodVaccines\/BloodBloodProducts\/ApprovedProducts\/LicensedProductsBLAs\/FractionatedPlasmaProducts\/ucm186264.htm. Accessed 17 Mar 2025."},{"key":"3656_CR148","unstructured":"US Food and Drug Administration. Medical officer clinical final review of original BLA: Berinert (C1-Esterase\u00a0Inhibitor [Human], Pasteurized). March 7, 2008. https:\/\/www.fda.gov\/vaccines-blood-biologics\/approved-blood-products\/berinert. Accessed 17 Mar 2025."},{"key":"3656_CR149","unstructured":"Subcutaneous treatment with icatibant for acute attacks of hereditary angioedema. ClinicalTrials.gov identifier: NCT00097695. https:\/\/clinicaltrials.gov\/study\/NCT00097695?term=NCT00097695&rank=1. Accessed 16 Mar 2025."},{"key":"3656_CR150","unstructured":"Longhurst HJ, Smith MD, Yea C, Audhya P. Sebetralstat effectiveness in the treatment of hereditary angioedema attacks rated mild or moderate at baseline in the phase\u00a02 trial. Presented at: ASCIA Congress; August 30-September 2, 2022; Melbourne, Australia."},{"key":"3656_CR151","unstructured":"Ayg\u00f6ren-P\u00fcrs\u00fcn E, Zanichelli A, Cohn DM, et al. Efficacy of the oral plasma kallikrein inhibitor sebetralstat (KVD900) by attack location in a phase\u00a02 clinical trial in patients with hereditary angioedema. Presented at: Western Society of Allergy, Asthma and Immunology (WSAAI) 60th Annual Scientific Session. February 5\u20139, 2023; Fairmont Orchid, Hawaii."},{"key":"3656_CR152","unstructured":"Farkas H, Riedl MA, Ayg\u00f6ren-P\u00fcrs\u00fcn E, et al. KONFIDENT-S interim analysis: sebetralstat for HAE attacks (including laryngeal). Presented at: Bradykinin Symposium; September 4\u20135, 2024; Berlin, Germany."},{"issue":"Suppl 2","key":"3656_CR153","doi-asserted-by":"publisher","first-page":"A51","DOI":"10.1186\/1710-1492-10-S2-A51","volume":"10","author":"W Yang","year":"2014","unstructured":"Yang W, H\u00e9bert J, Ritchie B, et al. Analysis of icatibant for the treatment of laryngeal hereditary angioedema attacks in the FAST-3 study. Allergy Asthma Clin Immunol. 2014;10(Suppl 2):A51.","journal-title":"Allergy Asthma Clin Immunol"},{"issue":"1","key":"3656_CR154","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1159\/000441060","volume":"168","author":"WR Lumry","year":"2015","unstructured":"Lumry WR, Farkas H, Moldovan D, et al. Icatibant for multiple hereditary angioedema attacks across the controlled and open-label extension phases of FAST-3. Int Arch Allergy Immunol. 2015;168(1):44\u201355.","journal-title":"Int Arch Allergy Immunol"},{"issue":"2","key":"3656_CR155","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2023.11.900","volume":"153","author":"M Riedl","year":"2024","unstructured":"Riedl M, Ayg\u00f6ren-P\u00fcrs\u00fcn E, Lumry W, et al. Sebetralstat for on-demand treatment of hereditary angioedema attacks: results of the double-blind, placebo-controlled phase\u00a03 KONFIDENT Trial. J Allergy Clin Immunol. 2024;153(2):AB375.","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"3656_CR156","doi-asserted-by":"publisher","first-page":"S28","DOI":"10.1016\/j.anai.2024.08.113","volume":"133","author":"W Lumry","year":"2024","unstructured":"Lumry W, Cohn D, Bernstein J, et al. Substantial reduction of hereditary angioedema attack symptom burden in the sebetralstat phase\u00a03 KONFIDENT trial. Ann Allergy Asthma Immunol. 2024;133(6):S28.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"3","key":"3656_CR157","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1016\/j.jaci.2024.12.1079","volume":"155","author":"DM Cohn","year":"2025","unstructured":"Cohn DM, Soteres DF, Craig TJ, et al. Interplay between on-demand treatment trials for hereditary angioedema and treatment guidelines. J Allergy Clin Immunol. 2025;155(3):726\u201339.","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"3656_CR158","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-022-02360-3","volume":"17","author":"M Jean-Baptiste","year":"2022","unstructured":"Jean-Baptiste M, Itzler R, Prusty S, Supina D, Martin ML. The symptom experience of hereditary angioedema (HAE) patients beyond HAE attacks: literature review and clinician interviews. Orphanet J Rare Dis. 2022;17(1):232. https:\/\/doi.org\/10.1186\/s13023-022-02360-3.","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"3656_CR159","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1002\/pds.5547","volume":"32","author":"EK Acton","year":"2023","unstructured":"Acton EK, Willis AW, Hennessy S. Core concepts in pharmacoepidemiology: key biases arising in pharmacoepidemiologic studies. Pharmacoepidemiol Drug Saf. 2023;32(1):9\u201318. https:\/\/doi.org\/10.1002\/pds.5547.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"6","key":"3656_CR160","doi-asserted-by":"publisher","first-page":"1614","DOI":"10.1016\/j.jaip.2024.04.007","volume":"12","author":"RS Petersen","year":"2024","unstructured":"Petersen RS, Fijen LM, Apfelbacher C, et al. A core outcome set for efficacy of acute treatment of hereditary angioedema. J Allergy Clin Immunol Pract. 2024;12(6):1614\u201321. https:\/\/doi.org\/10.1016\/j.jaip.2024.04.007.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"1","key":"3656_CR161","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1007\/s12325-024-03013-6","volume":"42","author":"A Igarashi","year":"2025","unstructured":"Igarashi A, Tanaka S, De Moor R, et al. Indirect treatment comparisons in healthcare decision making: a targeted review of regulatory approval, reimbursement, and pricing recommendations globally for oncology drugs in 2021-2023. Adv Ther. 2025;42(1):52\u201369. https:\/\/doi.org\/10.1007\/s12325-024-03013-6.","journal-title":"Adv Ther"},{"issue":"1","key":"3656_CR162","doi-asserted-by":"publisher","DOI":"10.1186\/s13223-025-00955-6","volume":"21","author":"HH Li","year":"2025","unstructured":"Li HH, Ayg\u00f6ren-P\u00fcrs\u00fcn E, Magerl M, et al. Indirect treatment comparison of oral sebetralstat and intravenous recombinant human C1 esterase inhibitor for on-demand treatment of hereditary angioedema attacks. Allergy Asthma Clin Immunol. 2025;21(1):10.","journal-title":"Allergy Asthma Clin Immunol"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03656-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-026-03656-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03656-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T09:02:42Z","timestamp":1787389362000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-026-03656-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,18]]},"references-count":162,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["3656"],"URL":"https:\/\/doi.org\/10.1007\/s12325-026-03656-7","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,18]]},"assertion":[{"value":"9 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Raffi Tachdjian has received research or consulting support from Astria Therapeutics, BioCryst Pharmaceuticals, Inc, CSL Behring, Ionis Pharmaceuticals, Intellia, KalVista Pharmaceuticals, Pharming Healthcare, Inc., Pharvaris, and Takeda Pharmaceutical Company Ltd; and provided speaker presentations for ARS Pharmaceuticals, AstraZeneca, BioCryst Pharmaceuticals, CSL Behring, Grifols, GSK, Pharming Healthcare, Inc., Sanofi-Regeneron, and Takeda Pharmaceuticals Company Ltd; John Anderson is a speaker bureau member for CSL Behring, Pharming Healthcare, Inc, BioCryst Pharmaceuticals, Inc, Takeda Pharmaceutical Company Ltd, AstraZeneca, and GSK; has received consulting fees from CSL Behring, Pharming Healthcare, Inc., BioCryst Pharmaceuticals, Inc, Pharvaris, Ionis Pharmaceuticals, Takeda Pharmaceutical Company Ltd, and Novartis AG; and is a clinical trial investigator for BioCryst Pharmaceuticals, Inc, CSL Behring, Pharvaris, KalVista Pharmaceuticals, Astria Therapeutics, Takeda Pharmaceutical Company Ltd, Novartis AG, and CellDex Therapeutics; Paranjoy Saharia and Sakshi Jindal received consulting fees from Pharming Healthcare, Inc.; Nami Park, Joseph R. Harper, Anurag Relan, Amanda Harrington, and Nihal Narsipur are employees of Pharming Healthcare, Inc.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}